Highs, Lows, & Legal Lessons

Highs, Lows, & Legal Lessons

High-altitude illness is a clinical diagnosis driven by recent ascent, symptom timing, and severity, not by labs alone. Acute mountain sickness, HACE, and HAPE can present independently, and severe disease demands descent. Separately, most acute sinusitis is viral, and casual fluoroquinolone prescribing can leave patients with permanent neuropathy. High-Altitude Illness Pearls Recent ascent history: Recent altitude exposure should immediately reshape the differential in patients with headache, nausea, dizziness, dyspnea, or altered mental status, even when they present far from the mountains. Spectrum not progression: AMS, HACE, and HAPE are best understood as parallel altitude syndromes rather than a tidy progression, so patients may arrive with cerebral and pulmonary features together. Hyperbaric hypoxia mechanism: Altitude illness is driven by lower barometric pressure rather than a change in oxygen percentage, making this a tissue-delivery problem when rapid ascent outpaces acclimatization. HACE red flag findings: Ataxia and altered mental status after ascent should be treated as high-altitude cerebral edema until proven otherwise, a neurologic emergency where delay is dangerous. HAPE treatment framing: HAPE is noncardiogenic pulmonary edema from hypoxic pulmonary vasoconstriction, so oxygen and descent matter while diuretics do not. We get into the common mimics in the episode. Recurrence and risk profile: A prior altitude illness history is a major warning sign, with recurrence around 60%, while physical fitness offers little protection if the ascent profile is aggressive. Sinusitis and Fluoroquinolone Legal Lessons Bacterial sinusitis criteria: True acute bacterial sinusitis is uncommon; the key patterns are persistent symptoms beyond 10 days or a double-worsening course, not isolated facial pain after a day or two. Watchful waiting default: Most sinusitis presentations are viral, and even suspected bacterial cases often support watchful waiting rather than reflex antibiotics, a distinction worth hearing in the chapter. Fluoroquinolone neuropathy risk: Fluoroquinolones can cause rapidly developing peripheral neuropathy that may be permanent, and the drug should be stopped immediately when concerning sensory symptoms appear. Small fiber neuropathy clue: Stocking-glove paresthesias with a normal EMG do not exclude medication injury; small fiber neuropathy may only declare itself on skin biopsy. Reassessment before escalation: Switching or escalating antibiotics without seeing the patient again creates both clinical error and medicolegal exposure, especially when the original sinusitis criteria were never documented. High-risk prescribing documentation: When a fluoroquinolone is truly necessary, the rationale and risk discussion need explicit documentation, including tendon and neuropathy counseling. The bedside dot-phrase template is shown in the episode.